{"id":"https://openalex.org/W3031970601","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.10029","title":"Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).","display_name":"Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3031970601","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.10029","mag":"3031970601"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.10029","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.10029","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.10029","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086165685","display_name":"Jason Alan Chesney","orcid":"https://orcid.org/0000-0003-0217-8278","observed_orcids":["https://orcid.org/0000-0003-0217-8278"]},"institutions":[{"id":"https://openalex.org/I142740786","display_name":"University of Louisville","ror":"https://ror.org/01ckdn478","country_code":"US","type":"education","lineage":["https://openalex.org/I142740786"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Alan Chesney","raw_affiliation_strings":["James Graham Brown Cancer Center, University of Louisville, Louisville, KY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"James Graham Brown Cancer Center, University of Louisville, Louisville, KY;","institution_ids":["https://openalex.org/I142740786"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049243227","display_name":"Igor J. Puzanov","orcid":"https://orcid.org/0000-0002-9803-3497","observed_orcids":["https://orcid.org/0000-0002-9803-3497"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Igor Puzanov","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN;","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001015275","display_name":"Frances A. Collichio","orcid":"https://orcid.org/0000-0001-9807-4240","observed_orcids":["https://orcid.org/0000-0001-9807-4240"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frances A. Collichio","raw_affiliation_strings":["Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC;","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089777560","display_name":"Mohammed M. Milhem","orcid":"https://orcid.org/0000-0003-4663-6824","observed_orcids":["https://orcid.org/0000-0003-4663-6824"]},"institutions":[{"id":"https://openalex.org/I126307644","display_name":"University of Iowa","ror":"https://ror.org/036jqmy94","country_code":"US","type":"education","lineage":["https://openalex.org/I126307644"]},{"id":"https://openalex.org/I4390039339","display_name":"University of Iowa Holden Comprehensive Cancer Center","ror":"https://ror.org/01jhe7086","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I126307644","https://openalex.org/I4390039339"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohammed M. Milhem","raw_affiliation_strings":["Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA;","institution_ids":["https://openalex.org/I126307644","https://openalex.org/I4390039339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044736874","display_name":"Axel Hauschild","orcid":"https://orcid.org/0000-0002-1212-9587","observed_orcids":["https://orcid.org/0000-0002-1212-9587"]},"institutions":[{"id":"https://openalex.org/I4210112713","display_name":"University Hospital Schleswig-Holstein","ror":"https://ror.org/01tvm6f46","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210112713"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Axel Hauschild","raw_affiliation_strings":["Schleswig-Holstein University Hospital, Kiel, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Schleswig-Holstein University Hospital, Kiel, Germany;","institution_ids":["https://openalex.org/I4210112713"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088148162","display_name":"Min Yi","orcid":"https://orcid.org/0000-0001-7766-4882","observed_orcids":["https://orcid.org/0000-0001-7766-4882"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Min Yi","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022572233","display_name":"Sumita S. Bhatta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sumita Bhatta","raw_affiliation_strings":["Amgen, Thousand Oaks, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen, Thousand Oaks, CA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029047150","display_name":"Rubina Ismail","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rubina Ismail","raw_affiliation_strings":["Amgen, Inc., Thousand Oaks, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen, Inc., Thousand Oaks, CA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001548963","display_name":"Claus Garbe","orcid":"https://orcid.org/0000-0001-8530-780X","observed_orcids":["https://orcid.org/0000-0001-8530-780X"]},"institutions":[{"id":"https://openalex.org/I8087733","display_name":"University of T\u00fcbingen","ror":"https://ror.org/03a1kwz48","country_code":"DE","type":"education","lineage":["https://openalex.org/I8087733"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Claus Garbe","raw_affiliation_strings":["Eberhard Karls University, T\u00fcbingen, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eberhard Karls University, T\u00fcbingen, Germany;","institution_ids":["https://openalex.org/I8087733"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074582149","display_name":"Parminder Pal Singh","orcid":"https://orcid.org/0000-0002-2851-6805","observed_orcids":["https://orcid.org/0000-0002-2851-6805"]},"institutions":[{"id":"https://openalex.org/I4210127938","display_name":"Mayo Clinic Hospital","ror":"https://ror.org/03660jn93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099","https://openalex.org/I4210127938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Parminder Singh","raw_affiliation_strings":["Mayo Clinic, Phoenix, AZ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Phoenix, AZ;","institution_ids":["https://openalex.org/I4210127938"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053602981","display_name":"Janice M. Mehnert","orcid":"https://orcid.org/0000-0001-9492-9264","observed_orcids":["https://orcid.org/0000-0001-9492-9264","https://orcid.org/0000-0002-1043-3008"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janice M. Mehnert","raw_affiliation_strings":["Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;","institution_ids":["https://openalex.org/I4390039325"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"10029","last_page":"10029"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9218999743461609,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9218999743461609,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.059300001710653305,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.9470000267028809},{"id":"https://openalex.org/keywords/talimogene-laherparepvec","display_name":"talimogene laherparepvec","score":0.9829999804496765},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.8600000143051147},{"id":"https://openalex.org/keywords/oncolytic-viruses","display_name":"oncolytic viruses","score":0.7559999823570251},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8949999809265137},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.9200000166893005},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9610000252723694},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5669999718666077},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6589999794960022},{"id":"https://openalex.org/keywords/post-hoc-analysis","display_name":"post hoc analysis","score":0.5809999704360962},{"id":"https://openalex.org/keywords/landmark-analysis","display_name":"landmark analysis","score":0.5410000085830688},{"id":"https://openalex.org/keywords/durable-response","display_name":"durable response","score":0.4059999883174896},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5870000123977661},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4399999976158142},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.621999979019165}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9488203525543213},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.763314425945282},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6574703454971313},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5844824314117432},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4939613938331604},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4916422963142395},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.43775779008865356},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.4372456669807434},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.41395437717437744},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.37349259853363037},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.364227294921875},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.3259105682373047},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.30421000719070435},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.21723824739456177},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.10029","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.10029","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.10029","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4372331756","https://openalex.org/W3098111277","https://openalex.org/W2427476638","https://openalex.org/W2342031043","https://openalex.org/W2891150560","https://openalex.org/W2763265527","https://openalex.org/W4292851027","https://openalex.org/W2803619375","https://openalex.org/W7117247216","https://openalex.org/W2966547989"],"abstract_inverted_index":{"10029":[0],"Background:":[1],"This":[2],"is":[3],"the":[4,9,24,28,66,89,95,102,220,230,404],"first":[5],"randomized":[6,113,208],"trial":[7,438],"testing":[8],"addition":[10],"of":[11,31,128,147,167,216,246,287,304,313],"an":[12,16,253],"oncolytic":[13],"virus":[14],"to":[15,93,115,172,210,213,418],"immune":[17],"checkpoint":[18],"inhibitor":[19],"for":[20,170,229,372,378],"advanced":[21,398],"melanoma.":[22],"At":[23],"3-year":[25,367],"(yr)":[26],"follow-up,":[27],"combination":[29],"(combo)":[30],"T-VEC":[32,121,388],"and":[33,37,68,99,150,202,272,295,348,376,413,426],"ipi":[34,45,119,390,393],"demonstrated":[35],"durable":[36],"statistically":[38],"superior":[39],"objective":[40],"response":[41,60,182,245,256],"rate":[42,62,369,384],"(ORR)":[43],"over":[44],"alone":[46,394],"(36.7%":[47],"vs.":[48,401],"16.0%;":[49],"odds":[50],"ratio,":[51],"3.0;":[52],"95%":[53],"Cl,":[54],"1.6\u20136.0;":[55],"P":[56,361],"=":[57,362],"0.002).":[58],"Complete":[59],"(CR)":[61],"was":[63,76,122,158,176,193,224,306,325,338,349,370,385,408],"21.4%":[64],"with":[65,70,107,329,334,343,358,374,380,387,392,397,410,415,433,435],"combo":[67,103,117,231,405],"6.0%":[69],"ipi.":[71],"Median":[72,302,336],"overall":[73,244],"survival":[74],"(OS)":[75],"not":[77,307,339],"reached":[78,308,340],"in":[79,101,327,332,341,356,395],"either":[80],"arm.":[81,104,232],"In":[82,403],"this":[83],"post":[84],"hoc":[85],"analysis,":[86],"we":[87],"utilized":[88],"3-yr":[90],"landmark":[91],"data":[92],"explore":[94],"relationship":[96],"between":[97],"CR":[98,247,305,330,344,375,383,407,416],"OS":[100,337,368],"Methods:":[105],"Pts":[106],"unresectable,":[108],"stage":[109,292],"IIIB-IV":[110],"melanoma":[111,399],"were":[112,198,207,275],"1:1":[114],"receive":[116],"or":[118],"alone.":[120],"administered":[123],"intratumorally":[124],"on":[125,144,164],"day":[126,145,165],"1":[127,131,146,166],"week":[129],"(wk)":[130],"at":[132,141],"106":[133],"plaque-forming":[134],"units":[135],"(PFU)/mL":[136],"followed":[137],"by":[138,178],"subsequent":[139],"doses":[140],"108":[142],"PFU/mL":[143],"wk":[148,168],"4,":[149],"every":[151,160,184],"2":[152],"wks":[153,162,186],"thereafter.":[154],"Ipi":[155],"(3":[156],"mg/kg)":[157],"given":[159],"3":[161],"starting":[163],"6":[169,319],"up":[171],"4":[173],"doses.":[174],"Response":[175],"assessed":[177],"investigators":[179],"per":[180],"immune-related":[181],"criteria":[183],"12":[185],"until":[187],"disease":[188],"progression.":[189],"The":[190,321,364],"primary":[191],"endpoint":[192],"ORR;":[194],"key":[195],"secondary":[196],"endpoints":[197],"OS,":[199,412],"progression-free":[200],"survival,":[201],"safety.":[203],"Results:":[204],"198":[205],"pts":[206,235,279,328,342,357,396,414],"(98":[209],"combo;":[211],"100":[212],"ipi).":[214],"As":[215],"February":[217],"25,":[218],"2019,":[219],"median":[221],"follow-up":[222],"time":[223],"40.0":[225],"mos":[226,351],"(range:":[227,309,345,352],"0.2\u201363.7)":[228],"Among":[233],"98":[234],"who":[236,250],"received":[237],"combo,":[238],"21":[239,278,314],"(21.4%)":[240],"had":[241,260,264,269,284,291,298],"a":[242],"best":[243],"including":[248],"8":[249],"converted":[251],"from":[252],"initial":[254],"partial":[255],"(PR),":[257],"15":[258],"(15.3%)":[259],"PR,":[261],"19":[262,312],"(19.4%)":[263],"stable":[265],"disease,":[266,271,294,425],"30":[267],"(30.6%)":[268],"progressive":[270],"13":[273],"(13.2%)":[274],"unevaluable.":[276],"Of":[277],"achieving":[280],"CR,":[281],"17":[282],"(81%)":[283],"ECOG":[285,421],"status":[286],"0,":[288],"16":[289,296],"(76.2%)":[290,297],"IIIB-IVM1a":[293],"no":[299],"visceral":[300],"metastases.":[301],"duration":[303],"5.4[+]\u201358.2[+]":[310],"mos);":[311],"CRs":[315],"lasted":[316],"more":[317],"than":[318,331,391],"months.":[320],"baseline":[322,428],"tumor":[323,429],"burden":[324],"lower":[326,427],"those":[333,379,434],"non-CR.":[335,381,436],"25.1[+]\u201363.7[+]":[346],"mos)":[347,355],"47.6":[350],"0.2[+]\u2013":[353],"63.7[+]":[354],"non-CR":[359],"(Log-rank":[360],"0.0005).":[363],"Kaplan\u2013Meier":[365],"estimated":[366],"100.0%":[371],"patients":[373],"52.3%":[377],"Conclusions:":[382],"higher":[386],"plus":[389],"(21.4%":[400],"6.0%).":[402],"arm,":[406],"associated":[409],"prolonged":[411],"tended":[417],"have":[419],"better":[420],"performance":[422],"status,":[423],"earlier-stage":[424],"burden,":[430],"as":[431],"compared":[432],"Clinical":[437],"information:":[439],"NCT01740297.":[440]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-06-05T00:00:00"}